Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in Vitro

Cancer Research

Volumn 60, Issue 21, 2000, Pages 6196-6200

  Collen, Annemie ^a   Smorenburg, Susanne M ^b   Peters, Erna ^a   Lupu, Florea ^c   Koolwijk, Pieter ^a   Van Noorden, Cornelis ^b   Van Hinsbergh, Victor W M ^a,d  

^a TNO   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN; LOW MOLECULAR WEIGHT HEPARIN; REVIPARIN; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ELECTRON MICROSCOPY; FIBRIN FORMATION; FIBRIN POLYMERIZATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; METASTASIS POTENTIAL; PRIORITY JOURNAL;

CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FIBRIN; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 0034326271     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Cancer and clotting - Trousseau's warning
2. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecularweight heparin administered at home
3. Comparison of low-molecular-weight heparin administered primarily at home with unfracfionated heparin administered in the hospital for proximal deep-vein thrombosis
4. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism
5. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
6. Inhibition of metastases by anticoagulants
7. Control of angiogenesis by heparin and other sulfated polysaccharides
8. Heparin and angiogenesis: A low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically
9. Effect of low molecular weight heparan sulphate on angiogenesis in the rat cornea after chemical cauterization
10. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
11. Induction of angiogenesis during the transition from hyperplasia to neoplasia
12. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis
13. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines
14. Neovascularization is associated with a switch to the export of FGF-2 in the multistep development of fibrosarcoma
15. HGF/SF in angiogenesis
16. New aspects of blood vessel growth: Tumor and tissue-derived angiogenesis factors
17. Angiogenic factors
18. Cooperative effect of TNFα, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity
19. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor
20. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules
21. The role of fibrin in tumor metastasis
22. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing
23. Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing
24. Role of fibrin and plasminogen activators in repair-associated angiogenesis: In vitro studies with human endothelial cells
25. The configuration of fibrin clots determines capillary morphogenesis and endothelial cell migration
26. The influence of fibrin structure on the formation and maintenance of capillary-like tubules
27. Size and density of fibrin fibers from turbidity
28. Fibrinogen and fibrin - Proteins with complex roles in hemostasis and thrombosis
29. Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis
30. An endothelial cell growth factor from bovine hypothalamus: Identification and partial characterization
31. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria
32. Differential distribution and modulation of expression of α1/β1 integrin on human endothelial cells
33. Effect of thrombin on the production of plasminogen activators and PA inhibitor-1 by human foreskin microvascular endothelial cells
34. Fibrin gel structure and clotting time
35. Endothelial proteoglycans inhibit FGF-2 binding and mitogenesis
36. Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells
37. Modulation of human endothelial cell proliferation and migration by fucoidan and heparin
38. Heparin oligosaccharides: Inhibitors of the biological activity of bFGF on Caco-2 cells
39. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
40. Angiogenesis: A paradigm for balanced extracellular proteolysis during cell migration and morphogenesis
41. Role and localization of urokinase receptor in the formation of new microvascular structures in fibrin matrices
42. Effect of fibrin structure on plasmin-mediated dissolution of plasma clots
43. Requirement of vascular integrin α β 3 for angiogenesis
44. VE-Cadherin mediates endothelial cell capillary tube formation in fibrin and collagen gels
45. Interaction of heparin with fibrinogen using surface plasmon resonance technology: Investigation of heparin binding site on fibrinogen
46. Fibrinogen binds to heparin: The relationship of the binding of other adhesive proteins to heparin
47. Thrombin cleavage enhances exposure of a heparin binding domain in the N-terminus of the fibrin β chain